Innovent Reports Trial Data from PD-1 Drug in Three Separate Indications

At the virtual ASCO conference, Suzhou Innovent announced clinical results from three trials of its PD-1 drug, Tyvyt®: • In a Phase II trial among patients with relapsed or refractory classic Hodgkin's lymphoma, the ORR was 85.4% and complete response (CR) 42.7%; • In a two-year study among patients with relapsed or refractory extranodal NK/T-cell lymphoma, the ORR was 67.9% and the CR 14.3%; • As a second-line treatment in patients with esophageal squamous cell carcinoma, the 12-month survival rates were 37.4% in the Tyvyt cohort and 21.4% in the chemotherapy group. In 2018, Tyvyt was approved for use in China as a third-line treatment for patients with classical Hodgkin's lymphoma. It is currently being tested in 20 clinical trials. More details.... Stock Symbol: (HK: 01801) Share this with colleagues: // //